Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant
- Brian M. Andersen1,
- Junzhe Xia2,
- Alan L. Epstein3,
- John R. Ohlfest4,
- Wei Chen5,
- Bruce R. Blazar5,
- Christopher A. Pennell†6 and
- Michael R. Olin†7Email author
© Andersen et al. 2016
Received: 5 November 2015
Accepted: 1 February 2016
Published: 16 February 2016
Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or heterotetramer. The secreted ANXA2 heterotetramer signals human and murine macrophages to produce IL-1, IL-6, and TNF-α through TLR4/MyD88- and TRIF-dependent pathways.
GL261 glioma cells were cultured in 5 % or 20 % O2. Monomeric ANXA2 (ANXA2m) was identified as a TLR2-binding protein enriched in 5 % O2 by mass spectrometry. Purified ANXA2m and ANXA2-derived peptides were added to TLR2-expressing reporter cells and immature dendritic cells (DCs) cells in vitro. ANXA2m was then mixed with chicken ovalbumin (OVA) for vaccination of TLR2 +/+ and TLR2 −/− mice for subsequent quantification of antigen-specific CD8+ T cell responses. The TLR2-binding region of ANXA2m was determined using various peptides derived from the ANXA2 amino terminus on TLR2 reporter cells and in vaccinated mice.
ANXA2m is overexpressed by murine glioblastoma GL261 cells grown under 5 % O2, but not atmospheric 20 % O2, and acts as an adjuvant by inducing murine and human DC maturation through TLR2. ANXA2m upregulates CD80 and CD86 expression, enhances antigen cross-presentation, and induces the secretion of IL-12p70, TNF-α, and IFN-γ. The amino-terminal 15 amino acids of ANXA2m are necessary and sufficient for TLR2 binding and DC activation.
This novel finding adds to the known functions of ANXA2 and suggests ways to exploit it as a vaccine adjuvant. ANXA2-antigen fusion peptides could be developed for patients as “off-the-shelf” agents containing common tumor antigens. Alternatively, they could be “personalized” and synthesized after tumor sequencing to identify immunogenic tumor-specific neo-antigens. As the amino terminal 15 amino acids of ANXA2 are required to stimulate TLR2 activity, a fusion peptide could be as short as 30 amino acids if one or two CD8 T cell epitopes are fused to the ANXA2 amino terminal portion. Future work will address the efficacy of ANXA2 peptide fusions alone and in combination with established TLR agonists to induce synergy in preclinical models of glioma as observed in other vaccines.
KeywordsAdjuvant Annexin Glioblastoma TLR2 Vaccine
Annexin A2 (ANXA2)4 is a broadly expressed member of the annexin family of calcium-dependent, anionic phospholipid-binding proteins. Annexins have homologous core and carboxyl domains but variable amino (N)-terminal regions with diverse binding and functional properties. These variable N-terminal 30 amino acid regions, called head regions, distinguish the family members . ANXA2 was first reported as an intracellular membrane-associated substrate of the pp60v-src oncoprotein in transformed chicken embryonic fibroblasts . ANXA2 is now known to be expressed by many cell types in the nucleus, cytoplasm, membrane, or extracellularly. Its many functions include membrane organization and dynamics during endocytosis and exocytosis, gene regulation, ion channel formation, fibrinolysis, and cellular transformation [3, 4]. The subcellular localization, post-translational modifications, and different binding partners of ANXA2 dictate its diverse functions.
A frequent binding partner of ANXA2 is the plasminogen receptor protein S100A10 . Upon binding to calcium, a conformational change occurs in ANXA2m that exposes a hydrophobic residue in its N terminus, allowing ANXA2m to bind a S100A10 dimer. This dimer bridges two ANXA2m to form a heterotetramer (ANXA2t) . ANXA2t binds anionic phospholipids with high affinity and correspondingly often localizes to the plasma membrane. ANXA2t can also be released from cells in exosomes (after Tyr-23 phosphorylation), via SNARE-mediated fusion with the plasma membrane, and through transmembrane channels (when chaperoned by PtdIns [4, 5] P2) [6–8]. Extracellular ANXA2t functions immunologically by inducing macrophages to release IL-1, IL-6, and TNF-α through TLR4/MyD88- and TRIF-dependent pathways .
Here we report for the first time that extracellular ANXA2m also functions immunologically, and that the monomeric and tetrameric forms of ANXA2 signal through different pathways. We find that ANXA2m, when released by cells, binds TLR2 and induces the differentiation of murine and human antigen presenting cells (APCs). ANXA2m induces the expression of CD80 and CD86, the secretion of IL-12, INF-γ, and TNF-α, and enhances the cross-priming of murine and human antigen-specific CD8+ T cells. All of these activities map to the unique N-terminus of ANXA2m. These data, combined with our observation that ANXA2m is over-expressed by murine GL261 glioblastoma cells grown under low (5 %) but not atmospheric (20 %) O2 levels, suggest ANXA2m is a novel danger-associated molecular pattern (DAMP) that contributes to the increased efficacy of tumor vaccines derived from GL261 cells grown under 5 % O2 .
Results and discussion
ANXA2m is an O2-regulated protein that binds TLR2
We reported that decreasing O2 from the typical tissue culture level of 20 to 5 % enhanced the adjuvant activity of lysates from murine GL261 glioma cells in a glioblastoma vaccination model . This led us to hypothesize that 5 % O2 enriched for the expression of DAMPs by GL261 cells that, in turn, activated APCs by binding to pattern recognition receptors. Because the pattern recognition receptor TLR2 was implicated in inflammation following hypoxia in the brain , we further hypothesized that TLR2 was required for recognizing O2-regulated putative DAMP expression in GL261 cells.
To identify the putative DAMP(s), we screened lysates from GL261 cells cultured under 5 % O2 for TLR2-binding molecules using immunoprecipitation. Subsequent mass spectrometry revealed ANXA2 was enriched in the TLR2-binding fraction (data not shown). Immunoblot analysis confirmed that ANXA2 was overexpressed in GL261 cells grown under 5 % O2 relative to 20 % O2 (Fig. 1b, top). Binding of ANXA2 and TLR2 was corroborated by co-immunoprecipitation (Fig. 1b, bottom; the <90 kDa bands in the anti-TLR2 immunoblot correspond to lower molecular weight TLR2 isoforms) . Together these data reveal ANXA2 is an O2-regulated protein that binds TLR2.
We next asked which form of ANXA2 bound TLR2, and if binding resulted in signal transduction. ANXA2m and ANXA2t were incubated in vitro with HEK-Blue reporter cells expressing human TLR2. Secretion of alkaline phosphatase by these reporter cells was induced by human ANXA2m, and the TLR2-signaling positive control Pam3CSK4 (a synthetic analogue of triacylated lipopeptide), but not by bovine ANXA2t (Fig. 1c). Heat denaturation or enzymatic degradation of human ANXA2m abolished signaling, showing the TLR2 binding moiety was proteinaceous and not a contaminating lipid moiety (Fig. 1d). Human ANXA2m did not induce alkaline phosphatase secretion by the HEK-Blue human TLR7 reporter cell line, showing the specificity of ANXA2m binding to TLR2 relative to TLR7 (data not shown).
Because ANXA2t binds and signals through TLR4 , we tested whether ANXA2m could do the same. We found that human ANXA2m was significantly superior to an equimolar amount of bovine ANXA2t at activating the HEK-Blue human TLR4 reporter cell line (Fig. 1e). Although ANXA2m is of human origin, and ANXA2t is bovine, the two ANXA2 proteins have identical head regions and share 99 % homology overall. It is therefore unlikely the enhanced signaling through human TLR4 of the monomer relative to the tetramer is due to species differences.
To determine if ANXA2m could enhance an antigen-specific T cell response, purified CD8+ T cells bearing the pmel-1 TCR were added to cultures of APCs from TLR4 −/− mice pulsed with the gp10025–33 peptide with or without human ANXA2m. ANXA2m significantly enhanced antigen-specific activation of pmel-1 CD8+ T cells, as measured by IFN-γ expression compared to the peptide alone (Fig. 1f). Together these data demonstrate ANXA2m, and not ANXA2t, binds and signals through TLR2, and the ANXA2m adjuvant effect does not require TLR4 or TLR7.
ANXA2m enhances murine and human antigen-specific CD8+ T cell responses
Unlocking the cross-priming potential of the DC is a cardinal requirement of tumor cell vaccines. Patient-derived immune suppression or poor immunogenicity of cell lysates can limit the impact of co-delivered synthetic adjuvants thereby diminishing DC activation and cross-priming. Therefore, we next asked whether the addition of ANXA2m to DC cultures could increase cross-priming.
To determine if ligation of TLR2 by human ANXA2m enhanced an antigen-specific immune response in vivo, we used a CD8+ T-cell priming model that rapidly expands antigen-specific CD8+ T cell frequencies . B6 and TLR −/− mice immunized with OVA plus human ANXA2m were bled and the frequencies of CD8+ T cells specific for the OVA-derived peptide, SIINFEKL, presented by H-2Kb, were determined by flow cytometry. Human ANXA2m significantly (P <0.001) increased the frequency of antigen-specific peripheral blood CD8+ T cells in wildtype but not TLR2 −/− mice (Fig. 2e). Together these data show human ANXA2m can signal through mouse TLR2 to enhance an antigen-specific immune response.
To determine the effect of human ANXA2m on antigen-specific human CD8+ T cell responses in vitro, we pulsed human monocyte-derived DCs from cytomegalovirus (CMV)-positive and -negative donors with a maturation cocktail and the pp65 CMV peptide in the presence or absence of human ANXA2m [16, 17]. The subsequent addition of patient-matched PBMCs led to a ten-fold increase in IFN-γ secretion in CMV seropositive samples when ANXA2m was present. This was an antigen-specific response as PMBCs from CMV seronegative individuals did not secrete IFN-γ in response to pp65 CMV plus ANXA2M (Fig. 2f). These data reveal ANXA2m enhances antigen-specific mouse and human CD8+ T cell responses, and suggest human ANXA2m can augment cross-priming in humans in vivo.
The N-terminal 15 amino acids of ANXA2m are necessary and sufficient for TLR2 binding and signaling
These studies leave open the question of ANXA2 as potential DAMP in vivo. ANXA2 expression is elevated in many tumors [3, 18], and in many cancers high levels of ANXA2 portend a poor prognosis . These observations are consistent with ANXA2 signaling through TLR2, as TLR2-induced inflammation is implicated in liver and colon tumor metastasis, for example . Our data suggest that immunogenic activity is absent or is overridden by other potentially tumor-promoting functions of ANXA2 [21–23], or by tumor-derived immune suppressive mechanisms such as regulatory T cells or myeloid-derived suppressor cells [24, 25]. It is also possible that ANXA2m is not present in great enough quantities, is sequestered, or exists in its tetrameric form that does not bind TLR2. The future may bring novel approaches to increase the immunogenicity of ANXA2 within tumor cells as a strategy to increase anti-tumor immunity in vivo.
C57BL/6 J (B6), Tlr2-B6.129-Tlr2tm1Kir/J (TLR2 −/−), and B6.B10ScN-Tlr4 lps-del /JthJ (TLR4 −/− ) mice were purchased from Jackson Laboratories and maintained in specific pathogen-free facilities at the University of Minnesota. The murine GL261 glioma model was established as described [10, 16]. Mice were immunized with 50 μg OVA plus 50 μg of the indicated peptides four consecutive days, and once more, 7 days following the first vaccine . All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
GL261 cells were cultured in DMEM/F12 (1:1) with L-glutamine, sodium bicarbonate, penicillin/streptomycin (100 U/mL), B27 and N2 supplements, and 0.1-mg/mL Normocin under 5 % or 20 % O2 as described . Splenocytes and T cells were cultured in RPMI 1640 containing 10 % heat-inactivated FBS, penicillin/streptomycin (100 U/ml), and 0.1 mg/ml Normocin.
GL261 cells were washed, pelleted, and lysed in radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Pierce). Lysates were diluted to the same protein concentration and were separated by 4–12 % SDS-PAGE. The separated proteins were then transferred to nitrocellulose, blocked, and incubated with mouse anti-ANXA2 (BD Biosciences). Blots were then washed and incubated with anti-mouse IgG HRP (Jackson ImmunoResearch). After additional washing, nitrocellulose was then incubated in ECL Plus chemiluminescent substrate (GE), drained, and exposed to HyBlot CL Autoradiography film (Denville Scientific).
Cold GL261 lysate was adjusted to a concentration of 2 mg/ml. Primary Ab was added to 0.5 ml lysate followed by overnight incubation at 4 °C with rocking. Protein A/G Agarose (Santa Cruz) was added and incubated at 4 °C with rocking. Beads were then washed, resuspended in reducing sample buffer, supernatants separated by 4–12 % SDS-PAGE, and transferred to nitrocellulose as described above for immunoblotting. The Abs were mouse anti-mouse TLR2 (Clone T2.5, Santa Cruz), mouse anti-mouse ANXA2 (Clone 5 BD Biosciences), and anti-mouse IgG HRP (Jackson ImmunoResearch).
Bone marrow-derived DC and TLR activity
For DC maturation experiments, B6 bone marrow-derived DCs (BMDCs) were generated using a modified protocol . Briefly, femurs and tibias were removed and flushed with saline. Erythrocytes were lysed, and remaining leukocytes were washed and placed in 10 cm dishes at 2 × 106 cells/10 ml in complete RPMI 1640 and 20 ng/ml GM-CSF (Peprotech). Non-adherent cells were removed and media were replaced every 3 days. Six days post-bone marrow harvest, loosely adherent cells were washed and plated in RPMI/GM-CSF.
HEK-Blue reporter cells stably express membrane-bound human TLR2 or human TLR4 and secrete alkaline phosphatase upon TLR stimulation (InvivoGen). HEK-Blue cells and BMDC swere stimulated with 50 ng/ml of the TLR2 agonist Pam3CSK4 (Imgenex), 2.5 μg/ml human ANXA2m (69 μM; AbD Serotec and Aviva Systems Biology), 6.5 μg/ml purified bovine ANXA2t (69 μM, Meridian), 5 μg/ml imiquimod, 2.6 μg/ml hu annexin A5 (69 μM, AbD Serotec), or 200 μg/ml ANXA2-OVA (STVHEILCKLSLEGDHSTPPSAYGSVKPYTNFDAEEQLESIINFEKLTEWT) peptides (residues 1–36 from ANXA2 followed by 16 OVA-derived aa). Control peptides, one containing the same content but scrambled order of the 36 ANXA2 aa (“Scrambled ANXA2-OVA,” GSCTESIEALHVLELVSPYTKSHNTPDSKGDYPFAEQLESIINFEKLTEWT), and one lacking the first 15 N terminal ANXA2 aa (“ANXA2ΔΝ15-OVA,” HSTPPSAYGSVKPYTNFDAEEQLESIINFEKLTEWT) were added to wells at levels equimolar to ANXA2-OVA. Forty-eight h following stimulation, BMDCs were stained and analyzed by flow cytometry, and HEK-Blue cell supernatant was assayed for secreted embryonic alkaline phosphatase activity using QuantiBlue colorimetric enzyme assay (InvivoGen). Enzymatic activity was recorded as an increase in OD640 after being normalized to media-only treatment.
Cross-priming and cross-presentation
Splenocytes from B6, TLR2 −/−, or TLR4 −/− mice were cultured at 2 × 105 cells/well in a 96-well plate in complete RPMI 1640 media. Splenocytes were pulsed with combinations of the following: 10 μg tumor lysate, 2.5 μg/ml human ANXA2m (AbD Serotec), or 50 μg/ml hu gp10025–33 peptide (KVPRNQDWL) or an OVA-derived peptide (EVSQLEQLESIINFEKLTEEWTSSNVM). For measurement of cross-presented OVA peptide, splenocytes were harvested, stained for CD11c, MHCII, and SIINFEKL/H-2Kb complex, and analyzed by flow cytometry as described below. To measure IFN-γ, CD8+ T lymphocytes were purified from pmel-1 mouse  splenocytes (Miltenyi Biotec), and 2 × 105 per well were co-cultured with unfractionated syngeneic splenocytes. Forty-eight hours after co-culture, IFN- γ was quantified in media using a flow cytometric bead array (BD Biosciences).
Cross-priming was tested in vivo through sequential daily vaccination as described [15, 27]. Briefly, B6 or TLR2 −/− mice were vaccinated four consecutive days with 100 μg OVA protein (with or without 1.5 μg human ANXA2m; AbD Serotec), 40 μg ANXA2-OVA peptide, or equimolar amounts of control peptides. Mice were boosted 3 days following the fourth vaccine, and bled the following day for analysis.
Analyses of labeled cell suspensions were performed on a custom Canto II (BD) and analyzed with FlowJo software (Tree Star, Inc.). Fluorochrome-conjugated mAbs used were CD11c—FITC (eBioscience, clone N418), CD86—PE (eBioscience, clone GL1), SIINFEKL-H-2Kb—PE (eBioscience, clone 25-D1.16) CD80—APC (eBioscience, clone 16-10A1), CD8α -APC (eBioscience, clone 53–6.7) and I-A/I-E—eFluor450 (MHC II; eBioscience, clone M5/114.15.2). The corresponding isotype controls were also purchased from eBioscience. A PE—dextran-conjugated multimer of SIINFEKL/H-2Kb was purchased from Immudex (Copenhagen, Denmark).
CMV antigen cross-priming by human monocyte-derived DCs
5 × 105 HLA-A2+ immature DCs were pulsed with 10 μg/ml of pp65495–503 (NLVPMVATV), with or without addition of 2.5 μg/ml human ANXA2m and matured. Purified donor-matched CD8 T cells were added and incubated as described previously .
monomeric annexin A2
tetrameric annexin A2
bone marrow-derived dendritic cell
danger-associated molecular pattern
median fluorescence intensity
- TLR2 −/− :
- TLR4 −/− :
B6.B10ScN-Tlr4 lps-del /JthJ
We thank the following people for their technical assistance and critique of this work: Joe Lalli, Rob Shaver, Dr. Zoe Zhang and Dr. Michelle Goulart. This work was supported by the National Cancer Institute/National Institutes of Health Grants R01CA154345 and R01CA72669. Randy Shaver Research and Community Fund.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5:219.1–8.View ArticleGoogle Scholar
- Erikson E, Erikson RL. Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product. Cell. 1980;21:829–36.View ArticlePubMedGoogle Scholar
- Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers. 2014;2014:308976–86.PubMed CentralPubMedGoogle Scholar
- Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14:6259–305.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnsson N, Marriott G, Weber K. p36, the major cytoplasmic substrate of src tyrosine protein kinase, binds to its p11 regulatory subunit via a short amino-terminal amphiphatic helix. EMBO J. 1988;7:2435–42.PubMed CentralPubMedGoogle Scholar
- Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011;286:30911–52.PubMed CentralView ArticlePubMedGoogle Scholar
- Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279:43411–8.View ArticlePubMedGoogle Scholar
- Danielsen EM, van Deurs B, Hansen GH. “Nonclassical” secretion of annexin A2 to the lumenal side of the enterocyte brush border membrane. Biochemistry. 2003;42:14670–6.View ArticlePubMedGoogle Scholar
- Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood. 2010;115:549–58.PubMed CentralView ArticlePubMedGoogle Scholar
- Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, et al. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res. 2010;16:4800–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007;104:13798–803.PubMed CentralView ArticlePubMedGoogle Scholar
- Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–80.PubMed CentralView ArticlePubMedGoogle Scholar
- LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol. 2003;171:6680–9.View ArticlePubMedGoogle Scholar
- Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6:715–26.View ArticlePubMedGoogle Scholar
- Wick DA, Martin SD, Nelson BH, Webb JR. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine. 2011;29:984–93.View ArticlePubMedGoogle Scholar
- Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, et al. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res. 2011;71:6583–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934–7.View ArticlePubMedGoogle Scholar
- Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28:1248–50.View ArticlePubMedGoogle Scholar
- D’Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012;119:1888–96.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim S, Karin M. Role of TLR2-dependent inflammation in metastatic progression. Ann NY Acad Sci. 2011;1217:191–206.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neuroscience. 2011;31:14346–60.View ArticlePubMedGoogle Scholar
- Kwon M, Caplan JF, Filipenko NR, Choi KS, Fitzpatrick SL, Zhang L, et al. Identification of annexin II heterotetramer as a plasmin reductase. J Biol Chem. 2002;277:10903–11.View ArticlePubMedGoogle Scholar
- Takahashi S, Reddy SV, Chirgwin JM, Devlin R, Haipek C, Anderson J, et al. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem. 1994;269:28696–701.PubMedGoogle Scholar
- Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology. 2011;13:591–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302.View ArticlePubMedGoogle Scholar
- Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693–702.View ArticlePubMedGoogle Scholar
- Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol. 2013;190:613–20.PubMed CentralView ArticlePubMedGoogle Scholar